Sensei Biotherapeutics (SNSE) Announces Addition to the Nasdaq Biotechnology Index

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.

The NBI was launched in 1993 and includes securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceutical companies. Companies in the NBI must meet eligibility requirements, including average daily trading volume, minimum market capitalization, and other criteria. The index is evaluated annually in December and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.

For more information about the NASDAQ Biotechnology Index, please visit nasdaqomx.com.

You May Also Be Interested In

• Z Squared outlines AI power strategy and Paradox Data acquisition
• Realty Income closes $1B convertible notes offering
• CleanCore Solutions to rename itself Zone Frontier Inc. on Aug. 31